The Unique Value Of Integrated Safety Services And Technology

By Archana Hegde, Senior Director, Integrated PV Solutions; Richard D’mello, Senior Director, Commercial Strategy And Operations; and Scott Fonseca, VP, Integrated Safety Managing Director

As the pharmaceutical industry adapts to accommodate evolving global regulatory requirements and ever-expanding digital touchpoints, drug safety and pharmacovigilance (PV) needs are changing. Adverse events are funneling in at higher volumes than ever before thanks to new digital reporting routes and heightened public awareness for drug safety following the COVID-19 pandemic. To respond to this volume and ensure patient safety, drug sponsors are looking to partner with innovative safety vendors that offer scalable models to meet demand.

Traditionally, the PV outsourcing model has included two vendors, one to provide innovative technology and another to offer PV expertise and services. However, this setup can yield gaps in communication, expensive contracts, and inefficient technology usage. Without a direct feedback loop between the PV technology and services vendors, it becomes difficult for them to make innovations that benefit the customer. To create a more efficient system, consider working with a vendor that leverages a combined services and technology model. In a single vendor system, technology is designed and built by those who will be using it, creating a smarter, more intuitive platform.

Download the full article to learn more about how this integration affords lower costs, better collaboration between stakeholders, more timely reporting of adverse events, and ultimately, continued accessibility of vital drugs.